pyrazines has been researched along with Genetic Predisposition in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (35.71) | 29.6817 |
| 2010's | 8 (57.14) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Ang, BT; Chong, YK; Koh, LWH; Lim, SW; Ng, WH; Sandanaraj, E; Tan, MSY; Tan, NS; Tan, P; Tang, C | 1 |
| Ang, GCK; Chang, KT; Guccione, E; Hebrard, M; Lee, VK; Leung, JY; Lim, HJ; Pal, A; Pignata, L; Rao, VK; Taneja, R | 1 |
| Bergsagel, PL; Chesi, M; Colonna, M; Ferrari de Andrade, L; Guillerey, C; Hill, GR; Martinet, L; Miles, K; Ngiow, SF; Ritchie, DS; Smyth, MJ; Teng, MW; Vuckovic, S; Yong, MC | 1 |
| Treon, SP | 1 |
| Adams, S; Barrett, AJ; Berg, M; Childs, R; Eniafe, R; Goldman, JM; Hensel, N; Keyvanfar, K; Lundqvist, A; Savani, BN; Sloand, EM; Yong, AS | 1 |
| Anderson, KC; Breitkreutz, I; Podar, K; Raab, MS; Richardson, PG | 1 |
| Bertsch, U; Broyl, A; Corthals, SL; de Knegt, Y; Durie, BG; el Jarari, L; Goldschmidt, H; Jongen, JL; Kuiper, R; Lokhorst, HM; Sonneveld, P; van der Holt, B; van Duin, M | 1 |
| Richardson, PG | 1 |
| Du, J; Fu, W; Hou, J; Huo, J; Jiang, H; Shi, J; Yi, Q; Yuan, Z; Zhang, C | 1 |
| Igaki, N; Yokota, K | 1 |
| Hanzis, C; Hunter, ZR; Ioakimidis, L; Manning, RJ; Patterson, CJ; Sheehy, P; Treon, SP; Tripsas, C; Turnbull, B | 1 |
| Akaza, H; Hattori, K; Iida, K; Itoh, K; Kawai, K; Kumagai, Y; Oyasu, R; Shimazui, T; Yamamoto, M | 1 |
| Bajaj, M; Cersosimo, E; Cusi, K; Gastaldelli, A; Kashyap, S | 1 |
| Brenner, DE; Krishnan, K; Ruffin, MT | 1 |
2 review(s) available for pyrazines and Genetic Predisposition
| Article | Year |
|---|---|
Multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Genetic Predisposition to Disease; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Neoplasm Staging; Protease Inhibitors; Pyrazines; Remission Induction; Stem Cell Transplantation; Survival Rate; Thalidomide; Treatment Outcome | 2009 |
Chemoprevention for colorectal cancer.
Topics: Adenoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Antioxidants; Apoptosis; Arachidonic Acids; Bile Acids and Salts; Biomarkers; Calcium; Cell Cycle; Cell Transformation, Neoplastic; Clinical Trials as Topic; Colonic Polyps; Colorectal Neoplasms; DNA Methylation; DNA Repair; Eflornithine; Enzyme Inhibitors; Estrogens; Free Radical Scavengers; Genetic Predisposition to Disease; Humans; Mice; Ornithine Decarboxylase Inhibitors; Patient Compliance; Patient Selection; Polyamines; Precancerous Conditions; Pyrazines; Rats; Retinoids; Thiones; Thiophenes; Tumor Cells, Cultured; Vitamins | 2000 |
2 trial(s) available for pyrazines and Genetic Predisposition
| Article | Year |
|---|---|
Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Chi-Square Distribution; Europe; Gene Expression Profiling; Gene Frequency; Genetic Predisposition to Disease; Humans; Middle Aged; Multiple Myeloma; Neoplasm Staging; Odds Ratio; Peripheral Nervous System Diseases; Polymorphism, Single Nucleotide; Prospective Studies; Pyrazines; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Vincristine; Young Adult | 2010 |
Effects on insulin secretion and insulin action of a 48-h reduction of plasma free fatty acids with acipimox in nondiabetic subjects genetically predisposed to type 2 diabetes.
Topics: Adult; Blood Glucose; C-Peptide; Circadian Rhythm; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Genetic Predisposition to Disease; Glucose Clamp Technique; Hormones; Humans; Hyperglycemia; Hypolipidemic Agents; Insulin; Insulin Secretion; Male; Osmolar Concentration; Pyrazines; Time Factors | 2007 |
10 other study(ies) available for pyrazines and Genetic Predisposition
| Article | Year |
|---|---|
A STAT3-based gene signature stratifies glioma patients for targeted therapy.
Topics: Animals; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Genetic Predisposition to Disease; Glioblastoma; Humans; Imidazoles; Insulin-Like Growth Factor Binding Protein 2; Mice; Pyrazines; Pyrazoles; Pyrimidines; Receptor, IGF Type 1; STAT3 Transcription Factor; Temozolomide; Xenograft Model Antitumor Assays | 2019 |
EHMT2 epigenetically suppresses Wnt signaling and is a potential target in embryonal rhabdomyosarcoma.
Topics: Animals; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Dimethyl Sulfoxide; Epigenesis, Genetic; Gene Expression Regulation, Developmental; Gene Expression Regulation, Neoplastic; Genetic Predisposition to Disease; Histocompatibility Antigens; Histone-Lysine N-Methyltransferase; Humans; Mice; Mice, Nude; Puromycin; Pyrazines; Pyridines; Quinazolines; Rhabdomyosarcoma, Embryonal; RNA Interference; Wnt Signaling Pathway | 2020 |
Immunosurveillance and therapy of multiple myeloma are CD226 dependent.
Topics: Animals; Antibodies, Monoclonal; Antigens, Differentiation, T-Lymphocyte; Antineoplastic Agents; Boronic Acids; Bortezomib; CD8-Positive T-Lymphocytes; Crosses, Genetic; CTLA-4 Antigen; Cyclophosphamide; Disease Progression; Genes, myc; Genetic Predisposition to Disease; Immunologic Surveillance; Immunotherapy; Interferon-gamma; Killer Cells, Natural; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Multiple Myeloma; Neoplasm Proteins; Neoplasm Transplantation; Pore Forming Cytotoxic Proteins; Programmed Cell Death 1 Receptor; Pyrazines; Receptors, Virus; Tumor Burden; Tumor Necrosis Factor Receptor Superfamily, Member 9 | 2015 |
How I treat Waldenström macroglobulinemia.
Topics: Adenine; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cladribine; Cyclophosphamide; Everolimus; Gene Expression; Genetic Predisposition to Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin M; Male; Middle Aged; Molecular Targeted Therapy; Myeloid Differentiation Factor 88; Nitrogen Mustard Compounds; Oligopeptides; Piperidines; Plasmapheresis; Pyrazines; Pyrazoles; Pyrimidines; Receptors, CXCR4; Rituximab; Sirolimus; Transplantation, Autologous; Vidarabine; Waldenstrom Macroglobulinemia | 2015 |
Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib.
Topics: Adolescent; Adult; Antigens, CD34; Boronic Acids; Bortezomib; Cell Separation; Cells, Cultured; Female; Gene Expression Regulation, Neoplastic; Genetic Predisposition to Disease; Genotype; Humans; Killer Cells, Natural; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Monomeric GTP-Binding Proteins; Pyrazines; Receptors, Death Domain; Up-Regulation | 2009 |
Towards a better understanding of treatment-related peripheral neuropathy in multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Gene Expression Profiling; Gene Frequency; Genetic Predisposition to Disease; Humans; Multiple Myeloma; Neoplasm Staging; Peripheral Nervous System Diseases; Polymorphism, Single Nucleotide; Pyrazines; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Vincristine | 2010 |
Polymorphisms of nuclear factor-κB family genes are associated with development of multiple myeloma and treatment outcome in patients receiving bortezomib-based regimens.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Boronic Acids; Bortezomib; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; Haplotypes; Humans; I-kappa B Proteins; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; NF-kappa B p52 Subunit; Polymorphism, Single Nucleotide; Pyrazines; Risk Assessment; Risk Factors; TNF Receptor-Associated Factor 3; Treatment Outcome | 2011 |
Sitagliptin (DPP-4 inhibitor)-induced rheumatoid arthritis in type 2 diabetes mellitus: a case report.
Topics: Alleles; Arthritis, Rheumatoid; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Genetic Predisposition to Disease; HLA-DRB1 Chains; Humans; Middle Aged; Pyrazines; Rheumatoid Factor; Sitagliptin Phosphate; Triazoles | 2012 |
Familial disease predisposition impacts treatment outcome in patients with Waldenström macroglobulinemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Cyclophosphamide; Disease Progression; Disease-Free Survival; Genetic Predisposition to Disease; Humans; Middle Aged; Pyrazines; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2012 |
Nrf2 is essential for the chemopreventive efficacy of oltipraz against urinary bladder carcinogenesis.
Topics: Animals; Anticarcinogenic Agents; Butylhydroxybutylnitrosamine; Carcinogens; DNA-Binding Proteins; Enzyme Induction; Female; Gene Expression; Genetic Predisposition to Disease; Glucuronides; Glucuronosyltransferase; Inactivation, Metabolic; Male; Mice; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Microsomes, Liver; NF-E2-Related Factor 2; Pyrazines; Thiones; Thiophenes; Trans-Activators; Urinary Bladder; Urinary Bladder Neoplasms | 2004 |